Issues and concerns in nanotech product development and its commercialization

Area of Science:

• Pharmaceutical Sciences
• Materials Science
• Biotechnology

Background:

• Nanotechnology's revolutionary potential is increasingly applied in pharmaceutical drug development.
• Despite growing research and funding, commercialization of nanotechnology-based pharmaceutical products lags.
• Nanotechnology addresses unmet needs like improving drug solubility, bioavailability, and toxicity profiles.

Purpose of the Study:

• To review the major challenges hindering the market translation of nanotechnology-based drug delivery systems.
• To elaborate on industry trends, US Food and Drug Administration (USFDA) regulatory roles, and implications.
• To identify obstacles for successful product development from laboratory to market.

Main Methods:

• Extensive literature survey and analysis of research publications.
• Expert review based on a decade of experience in nanotech-based drug delivery.
• Categorization and discussion of key commercialization barriers.

Main Results:

• Major impediments identified include inadequate regulatory frameworks and lack of public/physician/industry acceptance.
• Developmental challenges encompass scalability, reproducibility, characterization, quality control, and translation.
• Toxicological concerns, safety profiles, lack of multidisciplinary platforms, and intellectual property issues are also significant.

Conclusions:

• Successful translation of nanomedicines requires addressing regulatory, developmental, safety, and acceptance challenges.
• Overcoming these hurdles is crucial for realizing the full market potential of nanotechnology in pharmaceuticals.
• Collaboration and robust frameworks are needed to bridge the gap between lab research and market-ready products.